<p>Mersana Therapeutics（纳斯达克代码：MRSN - 获取免费报告）在周四的报告中被 Lifesci Capital 的研究分析师从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
<p>其他股票研究分析师最近也对该股票发布了报告。Guggenheim 在周五的报告中重新发布了对 Mersana Therapeutics 股票的 “中性” 评级。BTIG Research 在周四将 Mersana Therapeutics 的股票评级从 “买入” 下调至 “持有”。Truist Financial 在周四将 Mersana Therapeutics 的股票评级从 “买入” 下调至 “持有”，并将该公司的目标股价从 36.00 美元下调至 30.75 美元。Wedbush 在周四的研究报告中将 Mersana Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。最后，William Blair 在周四的报告中将 Mersana Therapeutics 的股票评级从 “强力买入” 下调至 “市场表现”。七位分析师对该股票给予了 “持有” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “减持”，平均目标股价为 38.19 美元。</p>
<p>获取 <strong>Mersana Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们对 Mersana Therapeutics 的最新股票分析</strong></p>
<h2>Mersana Therapeutics 价格表现</h2>
<p>在周四的交易中，纳斯达克代码：MRSN 的股票上涨了 0.49 美元，达到 27.92 美元。该公司交易了 419,769 股，相较于其平均交易量 194,946 股。Mersana Therapeutics 的 52 周低点为 5.21 美元，52 周高点为 70.73 美元。该股票的 50 日移动平均线为 9.34 美元，200 日移动平均线为 8.63 美元。该公司的市值为 1.3935 亿美元，市盈率为-1.91，贝塔值为 0.92。</p>
<p>Mersana Therapeutics（纳斯达克代码：MRSN - 获取免费报告）最后一次发布季度财报是在 11 月 14 日（周五）。该公司报告的每股收益（EPS）为-1.51 美元，低于分析师的共识预期-1.44 美元，差额为 0.07 美元。该公司在本季度的收入为 1101 万美元，而共识预期为 1420 万美元。卖方分析师预测 Mersana Therapeutics 在当前财政年度将发布-0.62 美元的每股收益。</p>
<h2>Mersana Therapeutics 的机构交易</h2>
<p>一些对冲基金最近对其在 MRSN 的持仓进行了调整。摩根大通在第二季度将其在 Mersana Therapeutics 的持仓增加了 156.6%。摩根大通现在拥有 130,094 股该公司的股票，价值 39,000 美元，此前在上个季度增持了 79,390 股。Invesco Ltd.在第一季度将其在 Mersana Therapeutics 的持仓增加了 109.3%。Invesco Ltd.现在拥有 114,863 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 59,991 股。Algert Global LLC 在第一季度将其在 Mersana Therapeutics 的持仓增加了 124.7%。Algert Global LLC 现在拥有 135,013 股该公司的股票，价值 46,000 美元，此前在上个季度增持了 74,930 股。CWM LLC 在第一季度将其在 Mersana Therapeutics 的持仓增加了 102,580.6%。CWM LLC 现在拥有 184,825 股该公司的股票，价值 64,000 美元，此前在上个季度增持了 184,645 股。最后，Marshall Wace LLP 在第二季度购买了 Mersana Therapeutics 的股票，价值约 68,000 美元。93.92% 的股票由机构投资者持有。</p>
<h2>Mersana Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Mersana Therapeutics, Inc 是一家临床阶段的生物制药公司，开发针对有未满足需求的癌症患者的抗体药物偶联物（ADC）。该公司开发了 XMT-1660，一种针对 B7-H4 的 Dolasynthen ADC 候选药物；以及 XMT-2056，一种免疫合成 ADC。它与 Janssen Biotech, Inc、Ares Trading SA、默克 KGaA 和 Asana BioSciences, LLC 进行 ADC 产品候选药物的研发合作。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Mersana Therapeutics 更好</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>你的感恩节投资计划：3 只受益于足球热潮的股票</li>
<li>如何在购买前评估一只股票</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
<li>什么是便士股票？全面指南</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Mersana Therapeutics 吗？</h2>
<p>在你考虑 Mersana Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意之前立即购买……而 Mersana Therapeutics 并不在名单上。</p>
<p>虽然 Mersana Therapeutics 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRSN

<p>Lifesci Capital 将 Mersana Therapeutics（NASDAQ:MRSN）的评级从 “强力买入” 下调至 “持有”。其他分析师，包括 Guggenheim、BTIG Research、Truist Financial、Wedbush 和 William Blair，也下调了该股票的评级。该股票的平均评级为 “减持”，目标价格为 38.19 美元。Mersana 的股价上涨至 27.92 美元，市值为 1.3935 亿美元。该公司报告了季度亏损，未能达到预期。机构投资者持有 93.92% 的股份。Mersana 开发用于癌症治疗的抗体药物偶联物（ADCs），并与多家生物科技公司合作</p>

<p>Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) was downgraded by research analysts at Lifesci Capital from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report issued on Thursday,Zacks.com reports.</p>
<div class="lb-trans"><p>Mersana Therapeutics（纳斯达克代码：MRSN - 获取免费报告）在周四的报告中被 Lifesci Capital 的研究分析师从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
</div><p>Other equities research analysts also recently issued reports about the stock. Guggenheim reissued a &#34;neutral&#34; rating on shares of Mersana Therapeutics in a report on Friday. BTIG Research lowered shares of Mersana Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday. Truist Financial downgraded shares of Mersana Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price target for the company from $36.00 to $30.75 in a report on Thursday. Wedbush lowered shares of Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday. Finally, William Blair cut shares of Mersana Therapeutics from a &#34;strong-buy&#34; rating to a &#34;market perform&#34; rating in a report on Thursday. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Reduce&#34; and an average price target of $38.19.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该股票发布了报告。Guggenheim 在周五的报告中重新发布了对 Mersana Therapeutics 股票的 “中性” 评级。BTIG Research 在周四将 Mersana Therapeutics 的股票评级从 “买入” 下调至 “持有”。Truist Financial 在周四将 Mersana Therapeutics 的股票评级从 “买入” 下调至 “持有”，并将该公司的目标股价从 36.00 美元下调至 30.75 美元。Wedbush 在周四的研究报告中将 Mersana Therapeutics 的股票评级从 “强力买入” 下调至 “持有”。最后，William Blair 在周四的报告中将 Mersana Therapeutics 的股票评级从 “强力买入” 下调至 “市场表现”。七位分析师对该股票给予了 “持有” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “减持”，平均目标股价为 38.19 美元。</p>
</div><p>Get <strong>Mersana Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Mersana Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Analysis on Mersana Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Mersana Therapeutics 的最新股票分析</strong></p>
</div><h2>Mersana Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ:MRSN traded up $0.49 during trading on Thursday, hitting $27.92. 419,769 shares of the company were exchanged, compared to its average volume of 194,946. Mersana Therapeutics has a 52-week low of $5.21 and a 52-week high of $70.73. The stock has a 50 day moving average of $9.34 and a 200 day moving average of $8.63. The company has a market cap of $139.35 million, a PE ratio of -1.91 and a beta of 0.92.</p>
<div class="lb-trans"><p>在周四的交易中，纳斯达克代码：MRSN 的股票上涨了 0.49 美元，达到 27.92 美元。该公司交易了 419,769 股，相较于其平均交易量 194,946 股。Mersana Therapeutics 的 52 周低点为 5.21 美元，52 周高点为 70.73 美元。该股票的 50 日移动平均线为 9.34 美元，200 日移动平均线为 8.63 美元。该公司的市值为 1.3935 亿美元，市盈率为-1.91，贝塔值为 0.92。</p>
</div><p>Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.44) by ($0.07). The company had revenue of $11.01 million during the quarter, compared to the consensus estimate of $14.20 million. Sell-side analysts forecast that Mersana Therapeutics will post -0.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Mersana Therapeutics（纳斯达克代码：MRSN - 获取免费报告）最后一次发布季度财报是在 11 月 14 日（周五）。该公司报告的每股收益（EPS）为-1.51 美元，低于分析师的共识预期-1.44 美元，差额为 0.07 美元。该公司在本季度的收入为 1101 万美元，而共识预期为 1420 万美元。卖方分析师预测 Mersana Therapeutics 在当前财政年度将发布-0.62 美元的每股收益。</p>
</div><h2>Institutional Trading of Mersana Therapeutics</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds have recently made changes to their positions in MRSN. JPMorgan Chase &amp; Co. grew its position in Mersana Therapeutics by 156.6% in the second quarter. JPMorgan Chase &amp; Co. now owns 130,094 shares of the company's stock worth $39,000 after acquiring an additional 79,390 shares in the last quarter. Invesco Ltd. lifted its stake in Mersana Therapeutics by 109.3% during the first quarter. Invesco Ltd. now owns 114,863 shares of the company's stock worth $40,000 after purchasing an additional 59,991 shares during the last quarter. Algert Global LLC boosted its holdings in shares of Mersana Therapeutics by 124.7% in the 1st quarter. Algert Global LLC now owns 135,013 shares of the company's stock worth $46,000 after purchasing an additional 74,930 shares in the last quarter. CWM LLC boosted its holdings in shares of Mersana Therapeutics by 102,580.6% in the 1st quarter. CWM LLC now owns 184,825 shares of the company's stock worth $64,000 after purchasing an additional 184,645 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Mersana Therapeutics during the 2nd quarter valued at about $68,000. 93.92% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近对其在 MRSN 的持仓进行了调整。摩根大通在第二季度将其在 Mersana Therapeutics 的持仓增加了 156.6%。摩根大通现在拥有 130,094 股该公司的股票，价值 39,000 美元，此前在上个季度增持了 79,390 股。Invesco Ltd.在第一季度将其在 Mersana Therapeutics 的持仓增加了 109.3%。Invesco Ltd.现在拥有 114,863 股该公司的股票，价值 40,000 美元，此前在上个季度增持了 59,991 股。Algert Global LLC 在第一季度将其在 Mersana Therapeutics 的持仓增加了 124.7%。Algert Global LLC 现在拥有 135,013 股该公司的股票，价值 46,000 美元，此前在上个季度增持了 74,930 股。CWM LLC 在第一季度将其在 Mersana Therapeutics 的持仓增加了 102,580.6%。CWM LLC 现在拥有 184,825 股该公司的股票，价值 64,000 美元，此前在上个季度增持了 184,645 股。最后，Marshall Wace LLP 在第二季度购买了 Mersana Therapeutics 的股票，价值约 68,000 美元。93.92% 的股票由机构投资者持有。</p>
</div><h2>Mersana Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Mersana Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.</p>
<div class="lb-trans"><p>Mersana Therapeutics, Inc 是一家临床阶段的生物制药公司，开发针对有未满足需求的癌症患者的抗体药物偶联物（ADC）。该公司开发了 XMT-1660，一种针对 B7-H4 的 Dolasynthen ADC 候选药物；以及 XMT-2056，一种免疫合成 ADC。它与 Janssen Biotech, Inc、Ares Trading SA、默克 KGaA 和 Asana BioSciences, LLC 进行 ADC 产品候选药物的研发合作。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Mersana Therapeutics</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Mersana Therapeutics 更好</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>你的感恩节投资计划：3 只受益于足球热潮的股票</li>
<li>如何在购买前评估一只股票</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
<li>什么是便士股票？全面指南</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJTTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MRSN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Mersana Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Mersana Therapeutics 吗？</h2>
</div><p>Before you consider Mersana Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Mersana Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mersana Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意之前立即购买……而 Mersana Therapeutics 并不在名单上。</p>
</div><p>While Mersana Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Mersana Therapeutics 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lifesci Capital 将 Mersana Therapeutics（NASDAQ:MRSN）的评级下调为持有